LBF20107PG11: Difference between revisions
No edit summary |
No edit summary |
||
| Line 11: | Line 11: | ||
|Chemical Synthesis= | |Chemical Synthesis= | ||
|Metabolism= | |Metabolism= | ||
|Biological Activity=15(R)-Prostaglandin E1 dosen't have biological significance but inhibit 15-hydroxy PGDH (IC50 value of 189 <FONT FACE="Symbol">m</FONT>M).[[Reference:Jarabak_J:Braithwaite_SS:,Arch. Biochem. Biophys.,1976,177,245|{{RelationTable/GetFirstAuthor|Reference:Jarabak_J:Braithwaite_SS:,Arch. Biochem. Biophys.,1976,177,245}}]] | |||
}} | }} | ||
{{Lipid/Footer}} | {{Lipid/Footer}} | ||
Revision as of 21:00, 6 January 2010
| LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
| IDs and Links | |
|---|---|
| LipidBank | XPR1737 |
| LipidMaps | LMFA03010055 |
| CAS | |
| KEGG | {{{KEGG}}} |
| KNApSAcK | {{{KNApSAcK}}} |
| mol | LBF20107PG11 |
| 15 (R) -Prostaglandin E1 | |
|---|---|
| |
| Structural Information | |
| 9-oxo-11α,15R-dihydroxy-prost-13E-en-1-oic acid | |
| |
| Formula | C20H34O5 |
| Exact Mass | 354.240624198 |
| Average Mass | 354.48096000000004 |
| SMILES | C(CC[C@H](O)C=C[C@H]([C@H]1CCCCCCC(O)=O)[C@@H](CC1=O)O)CC |
| Physicochemical Information | |
| 15(R)-Prostaglandin E1 dosen't have biological significance but inhibit 15-hydroxy PGDH (IC50 value of 189 mM). Jarabak_J et al. | |
| Spectral Information | |
| Mass Spectra | |
| UV Spectra | |
| IR Spectra | |
| NMR Spectra | |
| Other Spectra | |
| Chromatograms | |
| Reported Metabolites, References | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
